Scientists are exploring that possibility after years of clinical trials found that oral vitamin D supplements generally did not produce meaningful improvements in lung function, flare-ups or quality of life for people with COPD, asthma and cystic fibrosis.
A 2026 scientific perspective proposes that the delivery route may be part of the problem. After vitamin D is swallowed, it is processed by the liver and diluted through the bloodstream. The researchers suggest that an inactivating enzyme highly expressed in the lung’s blood vessels may also break it down before enough active vitamin reaches the airway surface.
Delivering vitamin D directly to the airways through a specially formulated inhaler or nebulizer could potentially bypass that obstacle. In laboratory cells and animal models, pulmonary vitamin D has shown promising effects, including reduced inflammation, stronger airway barriers, improved antimicrobial defenses and, in some models, better lung function.
But this is not yet an approved or proven treatment. No clinical trials have tested inhaled vitamin D in people with chronic lung disease, so researchers still need to establish its safety, formulation, dosage and real-world effectiveness.
The concept is promising because it treats the lungs as a direct target—but patients should never crush, vaporize or inhale ordinary vitamin D supplements. Only medically developed formulations should ever be tested this way.
0 commentaires:
Enregistrer un commentaire